These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 17487746)

  • 21. [Clinical study of primary central nervous system lymphoma: the role of chemotherapy].
    Maeda Y; Matsumoto K; Kuriyama M; Ono Y; Kunishio K; Tamiya T; Furuta T; Ohmoto T
    Gan To Kagaku Ryoho; 1997 May; 24(7):807-13. PubMed ID: 9170518
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Treatment of primary intraocular lymphoma with rituximab, high dose methotrexate, procarbazine, and vincristine chemotherapy, reduced whole-brain radiotherapy, and local ocular therapy.
    Taoka K; Yamamoto G; Kaburaki T; Takahashi T; Araie M; Kurokawa M
    Br J Haematol; 2012 Apr; 157(2):252-4. PubMed ID: 22085111
    [No Abstract]   [Full Text] [Related]  

  • 23. A Rare Case of Primary Central Nervous System Lymphoma in an Adolescent Female Treated with High-Dose Methotrexate and Rituximab-Based Chemoimmunotherapy and Consolidation Whole Brain Radiotherapy.
    Biswas A; Adhikari N; Bakhshi S; Gopinathan VR; Sharma MC
    Pediatr Neurosurg; 2019; 54(1):57-65. PubMed ID: 30669145
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Medical management of primary central nervous system lymphoma refractory or resistant to standard of care treatment].
    Yamanaka R
    Brain Nerve; 2009 Oct; 61(10):1155-64. PubMed ID: 19882942
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Survival improvement with combined radio-chemotherapy in the primary central nervous system lymphomas.
    Wu HG; Kim IH; Ha SW; Park CI; Bang YJ; Huh DS
    J Korean Med Sci; 1999 Oct; 14(5):565-70. PubMed ID: 10576154
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Impact of therapeutic regimen and clinical presentation on overall survival in CNS lymphoma.
    Kellogg RG; Straus DC; Karmali R; Munoz LF; Byrne RW
    Acta Neurochir (Wien); 2014 Feb; 156(2):355-65. PubMed ID: 24078063
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Current status and future of relapsed primary central nervous system lymphoma (PCNSL).
    Tyson RM; Siegal T; Doolittle ND; Lacy C; Kraemer DF; Neutwelt EA
    Leuk Lymphoma; 2003 Apr; 44(4):627-33. PubMed ID: 12769339
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Immunochemotherapy with rituximab and temozolomide for central nervous system lymphomas.
    Pitini V; Arrigo C; Righi M
    Cancer; 2004 Dec; 101(12):2900-1; author reply 2901-2. PubMed ID: 15529311
    [No Abstract]   [Full Text] [Related]  

  • 29. Impact of central nervous system (CNS) prophylaxis on the incidence and risk factors for CNS relapse in patients with diffuse large B-cell lymphoma treated in the rituximab era: a single centre experience and review of the literature.
    Guirguis HR; Cheung MC; Mahrous M; Piliotis E; Berinstein N; Imrie KR; Zhang L; Buckstein R
    Br J Haematol; 2012 Oct; 159(1):39-49. PubMed ID: 22849793
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Intravenous methotrexate as central nervous system (CNS) prophylaxis is associated with a low risk of CNS recurrence in high-risk patients with diffuse large B-cell lymphoma.
    Abramson JS; Hellmann M; Barnes JA; Hammerman P; Toomey C; Takvorian T; Muzikansky A; Hochberg EP
    Cancer; 2010 Sep; 116(18):4283-90. PubMed ID: 20564149
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Methotrexate area under the curve as a prognostic factor in primary central nervous system lymphoma treated with immunochemoradiotherapy.
    Morris PG; Abrey LE; Reiner AS; Wu N; Panageas KS; Seko BS; Deangelis LM; Omuro A
    Leuk Lymphoma; 2011 Oct; 52(10):1891-7. PubMed ID: 21699456
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Salvage chemoimmunotherapy with rituximab, ifosfamide and etoposide (R-IE regimen) in patients with primary CNS lymphoma relapsed or refractory to high-dose methotrexate-based chemotherapy.
    Mappa S; Marturano E; Licata G; Frezzato M; Frungillo N; Ilariucci F; Stelitano C; Ferrari A; Sorarù M; Vianello F; Baldini L; Proserpio I; Foppoli M; Assanelli A; Reni M; Caligaris-Cappio F; Ferreri AJ
    Hematol Oncol; 2013 Sep; 31(3):143-50. PubMed ID: 23161567
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Preradiotherapy chemotherapy in primary CNS lymphomas: progress?].
    Schwegler N
    Strahlenther Onkol; 1997 Feb; 173(2):117-8. PubMed ID: 9072839
    [No Abstract]   [Full Text] [Related]  

  • 34. Combined treatment with high-dose methotrexate, vincristine and procarbazine, without intrathecal chemotherapy, followed by consolidation radiotherapy for primary central nervous system lymphoma in immunocompetent patients.
    Ferreri AJ; Reni M; Dell'Oro S; Ciceri F; Bernardi M; Camba L; Ponzoni M; Terreni MR; Tomirotti M; Spina M; Villa E
    Oncology; 2001; 60(2):134-40. PubMed ID: 11244328
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Chemoradiotherapy for primary CNS lymphoma: an intent-to-treat analysis with complete follow-up.
    Omuro AM; DeAngelis LM; Yahalom J; Abrey LE
    Neurology; 2005 Jan; 64(1):69-74. PubMed ID: 15642906
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Treatment of newly diagnosed B-cell origin primary CNS lymphoma with systemic R-IDARAM chemotherapy and intrathecal immunochemotherapy.
    Qian L; Zhou C; Shen J; Cen J; Yin W
    Oncotarget; 2016 May; 7(18):25783-90. PubMed ID: 27029056
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [II. Primary treatment of CNS lymphoma with high-dose MTX].
    Iwadate Y
    Gan To Kagaku Ryoho; 2012 Jun; 39(6):892-7. PubMed ID: 22880222
    [No Abstract]   [Full Text] [Related]  

  • 38. PCV salvage chemotherapy for recurrent primary CNS lymphoma.
    Herrlinger U; Brugger W; Bamberg M; Küker W; Dichgans J; Weller M
    Neurology; 2000 Apr; 54(8):1707-8. PubMed ID: 10762527
    [No Abstract]   [Full Text] [Related]  

  • 39. High-dose methotrexate-based immuno-chemotherapy for elderly primary CNS lymphoma patients (PRIMAIN study).
    Fritsch K; Kasenda B; Schorb E; Hau P; Bloehdorn J; Möhle R; Löw S; Binder M; Atta J; Keller U; Wolf HH; Krause SW; Heß G; Naumann R; Sasse S; Hirt C; Lamprecht M; Martens U; Morgner A; Panse J; Frickhofen N; Röth A; Hader C; Deckert M; Fricker H; Ihorst G; Finke J; Illerhaus G
    Leukemia; 2017 Apr; 31(4):846-852. PubMed ID: 27843136
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Imaging and therapy with rituximab anti-CD20 immunotherapy in an animal model of central nervous system lymphoma.
    Muldoon LL; Lewin SJ; Dósa E; Kraemer DF; Pagel MA; Doolittle ND; Neuwelt EA
    Clin Cancer Res; 2011 Apr; 17(8):2207-15. PubMed ID: 21385922
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.